TrialBritish journal of cancer1993

A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects.

L T Vlasveld et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.